Category Archives: Embryology

PINNACLE FERTILITY ANNOUNCES THE PROMOTION OF BETH … – PR Newswire

SCOTTSDALE, Ariz., March 29, 2023 /PRNewswire/ -- Pinnacle Fertility (Pinnacle), the nation's fast-growing physician-led fertility care platform, is proud to announce the promotion of Beth Zoneraich to Chief Executive Officer (CEO) of Pinnacle Fertility. Beth brings over two decades of experience in scaling businesses and unparalleled expertise in fertility practice innovation and development. Under Beth's leadership, the Pinnacle team will be able to catalyze the transformation of patient care, outcomes, and experience across the Pinnacle network.

Jerry Rhodes, Executive Chairman - Pinnacle Fertility, said, "Beth's appointment as our CEO allows us to leverage her exceptional skills and expertise to steer Pinnacle Fertility's expansion worldwide. We are excited about the future of fertility healthcare and are confident that Beth's vision, integrity, and leadership will be instrumental in our team's success."

Beth joined Pinnacle Fertility as Chief Operating Officer in October 2021, concurrently with the acquisition of Advanced Fertility Care, where she had served as Co-Founder and CEO. At Pinnacle, Beth pioneered the Pinnacle Embryology School in collaboration with the Medical, Lab, and Business Leadership Boards. Alongside Dr. John Jain of Santa Monica Fertility, Beth has assisted in the expansion of Pinnacle's third-party reproduction services through the launch of Pinnacle Surrogacy and Pinnacle Egg Bank. These key partnerships and operational improvements have been essential to Pinnacle's tremendous growth.

Beth Zoneraich remarked, "At Pinnacle Fertility, we are passionate about helping families experience the miracle of parenthood. I joined Pinnacle for its commitment to a patient-first vision and a collaborative, physician-led approach. By setting the gold standard in fertility medicine and prioritizing exceptional patient experiences and successful outcomes, we are poised for significant growth. I am honored to work alongside this compassionate and talented team."

Pinnacle Fertility encompasses 34 top-tier fertility clinics and comprehensive fertility service providers across the nation. The Pinnacle network boasts some of the top 100 fertility clinics in the country, renowned for their innovation, success, and dedication to compassionate, patient-centric care.

About Pinnacle Fertility

Pinnacle Fertility is a patient-first, physician-led fertility care platform, supporting high-performing fertility clinics and comprehensive fertility service providers nationwide. Under a united mission of fulfilling dreams by building families, Pinnacle clinics offer innovative technology and processes, compassionate patient care, and comprehensive fertility treatment services, ensuring families receive a high-touch experience on their path to parenthood.

For more information about Pinnacle Fertility, visit pinnaclefertility.com.

Contact:Walt Conrad[emailprotected]

SOURCE Pinnacle Fertility

Read this article:
PINNACLE FERTILITY ANNOUNCES THE PROMOTION OF BETH ... - PR Newswire

Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of – EIN News

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Rumi Scientific (Rumi), a developer of therapies for rare and neurodegenerative diseases discovered using its high throughput organoid phenotypic screening platform, announced the appointment of Allen Fienberg, Ph.D., as Chief Executive Officer (CEO) and Chairman of the Board of Directors.

Our human organoid-based high throughput drug discovery platform has already identified multiple molecules and targets warranting further development, said Ali H. Brivanlou, Ph.D., co-founder of Rumi Scientific, and the Robert and Harriet Heilbrunn Professor and head of the Laboratory of Synthetic Embryology at The Rockefeller University. Having reached this point, it became clear that a CEO with expertise in advancing preclinical programs to clinical-stage candidates was needed to drive our continued progress. Allens extensive neuroscience research and drug development experience positions him ideally to lead the advancement of our lead program in Huntingtons disease (HD) and of our earlier-stage programs in autism spectrum disorder and Alport syndrome. On behalf of the Rumi Scientific team, I am pleased to welcome Allen to the Company and look forward to its ongoing evolution under his leadership.

Dr. Fienberg joined Rumi after serving for more than 20 years as Vice President of Business Development at Intra-Cellular Therapies, Inc. (ITI), which he co-founded in 2002. While at ITI, he was responsible for all business development activities along with various preclinical science initiatives. As a co-founder Dr. Fienberg also participated in early-stage fundraising, investor relations, legal and various administrative functions. From 1999-2001, Dr.Fienberg was a staff scientist at the Genomics Institute of the Novartis Research Foundation and was appointed a Research Assistant Professor at The Rockefeller University from 2001-2002. Dr.Fienberg earned his A.B. degree in Genetics from the University of California, Berkeley, and his Ph.D. in Human Genetics from Yale University. He completed post-doctoral studies at The Rockefeller University under the direction of the late Dr.Paul Greengard from 1991-1999.

What attracted me to Rumi was their highly innovative, phenotype-based drug discovery capabilities based on their unique high throughput organoid screening platform, said Dr. Fienberg. The platform evaluates drug-induced changes in phenotypes observed in neural organoids, rather than employing the traditional approach of identifying targets against which molecules are then tested. The platform has already identified molecules with the potential to impact several underlying pathological processes in HD. The platform is adaptable to almost any disease and thus has tremendous potential. I look forward to working with the talented team at Rumi to advance this and other potential therapeutic candidates.

About Rumi ScientificRumi Scientifics mission is to identify and develop novel therapeutics for rare and neurodegenerative diseases by employing its revolutionary synthetic human tissue platform to produce more predictive data leading to a safe and faster clinical trial process. The Companys lead program is an orally available bromodomain-containing protein 9 (BRD9) inhibitor in lead optimization for the treatment of Huntingtons disease. Founded in 2016, Rumi licensed foundational technology from The Rockefeller University developed by co-foundersAli H. Brivanlou, Ph.D., and Eric D. Siggia, Ph.D. For more information on Rumi Scientific, please see http://www.rumiscientific.com or contact info@rumiscientific.com.

Rumi Scientific:Allen Fienberg, Ph.D.Chairman and Chief Executive Officerallen@rumiscientific.com

Fred Etoc, Ph.D.Chief Scientific Officerfred@rumiscientific.com

Investors:Burns McClellan Lee Roth / Cameron Radinoviclroth@burnsmc.com / cradinovic@burnsmc.com

View original post here:
Rumi Scientific Appoints Allen A. Fienberg, Ph.D., as Chief Executive Officer and Chairman of the Board of - EIN News

Delay in early development of the embryo associated with likelihood of miscarriage – News-Medical.Net

Embryos in pregnancies that end in miscarriage take longer to develop in the womb than those in pregnancies that result in live births, according to new research published today (Monday) in Human Reproduction, one of the world's leading reproductive medicine journals.

For the first time, researchers in The Netherlands have been able to look at the way embryos develop while pregnancies are ongoing. They used state-of-the-art imaging technology, including 3D ultrasound with high resolution transvaginal probes and virtual reality techniques, to create 3D holograms of the embryo.

This enabled them to assess the overall development of the embryo, including arms and legs, the shape and length of the brain and the curvature of the embryo. 3D ultrasound and virtual reality techniques also enabled them to measure embryonic volume and the distance between the crown of the head and the bottom of the embryo's buttocks (crown-rump length).

Dr Melek Rousian, a gynecologist at Erasmus MC, University Medical Center, Rotterdam, The Netherlands, who led the study, said: "We found that in the first ten weeks of the pregnancy, embryos in pregnancies that end in a miscarriage took four days longer to develop than babies that did not miscarry. We also found that the longer it takes for an embryo to develop, the more likely it is to miscarry.

"In the future, the ability to assess the shape and development of embryos could be used to estimate the likelihood of a pregnancy continuing to the delivery of a healthy baby. This would enable health professionals to provide counseling to women and their partners about the prospective outcome of the pregnancy and the timely identification of a miscarriage. This would be particularly useful for couples who have had previous pregnancies that have ended in miscarriage; we might be able to indicate the risk of another miscarriage or maybe offer some early reassurance."

The researchers collected data from women taking part in the ongoing Rotterdam Periconception Cohort (PREDICT study), a large prospective study embedded in patient care in the department of obstetrics and gynecology at Erasmus MC, University Medical Center, Rotterdam. A total of 611 ongoing pregnancies and 33 pregnancies ending in a miscarriage were included from women recruited to the study between 2010 and 2018 when they were between seven and ten weeks pregnant.

To study the internal and external characteristics and measurements of an embryo, known as embryo morphology, the ability to see the embryo in 3D is important. The researchers used virtual reality to create holograms to look at the embryos' development and they compared the morphology against established stages of embryo development, known as the Carnegie Stages.

Without the aid of 3D and virtual reality, it is far more difficult to examine the development of the embryo. For instance, the 3D virtual reality technology makes it much easier to see the development of the arms and legs. In the Carnegie staging system, the curvature and position of the arms and legs have an important role. Many historic studies have examined the products of miscarriage, but this is the first time we have been able to look at the developing pregnancy while the pregnancy was still intact."

Dr Carsten Pietersma, first author of the study, PhD candidate and ultrasonographer at Erasmus MC

The Carnegie stages of embryonic development cover the first ten weeks of gestation and run from 1 to 23. Compared to an ongoing pregnancy, a pregnancy ending in a miscarriage was associated with a lower Carnegie stage and the embryo would reach the final Carnegie stage four days later than an embryo from a pregnancy that resulted in a healthy baby. A delay in Carnegie stage increased the likelihood of a miscarriage by 1.5% per delayed stage.

After the tenth week there is no staging system for embryo development, and so the researchers used foetal growth and birth weight to assess development thereafter. They found that a pregnancy ending in a miscarriage was linked to a shorter crown-rump length and smaller embryonic volume.

"We are able to show a significant association between miscarriage and a delay in the early development of the embryo, even if the miscarriage was after ten weeks of gestation," said Dr Pietersma.

The researchers adjusted their analyses to take account of factors that could affect pregnancy outcomes such as whether or not the women had been pregnant previously, age, ethnicity, socio-economic status, alcohol use, smoking and use of folic acid or other vitamin supplements.

A limitation of the study is that it includes a relatively small number of pregnancies that ended in miscarriage from a group of women attending tertiary care hospital for preconception and prenatal care and so they may not be representative of the general population. Results of genetic testing following a miscarriage were not available to the researchers, so they do not know if the embryos that miscarried had abnormal chromosome numbers, which could have contributed to the non-viability of the pregnancies.

Dr Denny Sakkas is Chief Scientific of Boston IVF (USA) and the embryology specialist deputy editor of Human Reproduction. He was not involved with the study. He said: "The emotional burden of a miscarriage is incredibly high for women with established pregnancies. This novel study by Carsten Pietersma and colleagues examines the development of embryos in the womb and finds differences in pregnancies that end in miscarriage compared to those that result in live births. The stages of development are calculated from examination of holograms generated from state-of-the-art 3D ultrasound imaging and virtual reality. Use of this technology could prepare patients for an early adverse pregnancy outcome, possibly allowing them to obtain supportive care in case of an adverse outcome."

Source:

Journal reference:

Pietersma, C. S., et al. (2023). Embryonic morphological development is delayed in pregnancies ending in a spontaneous miscarriage. Human Reproduction. doi.org/10.1093/humrep/dead032.

Read this article:
Delay in early development of the embryo associated with likelihood of miscarriage - News-Medical.Net

Human Fertilisation and Embryology Authority consults on proposed … – Solicitors Journal

The HFEA has proposed changes that it believes should be made to modernise the law

The Human Fertilisation and Embryology Authority (HFEA) launched a public consultation on 28 February on proposed changes to the law on fertility treatment regulation and embryo research. The consultation comes in response to the UK governments request that the HFEA puts forward recommendations for change.

The impetus for the review centres on the Human Fertilisation and Embryology Act 1990, which is over 30 years old, and has only been updated once since its enactment to reflect the significant changes in the fertility sector. Changes cited by the HFEA that have occurred in the past three decades include: changing attitudes to fertility treatment, evolutions in the science as well as new technologies, debates around new ethical issues and treatment options, and changes to the size of the sector and the services offered. The regulator also highlights limitations to its powers compared to some other UK regulators that have a wider and more effective range of powers to improve compliance and protect patients and consumers than those available to the HFEA.

The only changes to the law were implemented in 2008, focusing on new treatment options for parents seeking to avoid serious inherited mitochondrial disorders, removing potential barriers to licensed treatment for female same-sex couples, and widening the scope of who could become a parent. Other related changes brought about through regulations or secondary legislation include: enabling complex data to be shared with researchers to explore infertility and the impact of IVF, and changes to the storage period for gametes and embryos.

The changes proposed in the consultation are grouped into four areas: patient safety and promoting good practice; access to donation information; consent; and scientific developments. The proposed changes related to scientific developments includes measures to future proof the law to ensure it is better able to respond to scientific developments and therefore speed up potential access tonew treatment options for patients. It is envisaged that this would allow Parliament to approve new scientific and clinical developments through regulation without having to modifythe Human Fertilisation and Embryology Act every time.

The consultation is open for feedback until 14 April 2023. Following the consultation, the HFEA will submit its final recommendations to the Department of Health and Social Care.

Continued here:
Human Fertilisation and Embryology Authority consults on proposed ... - Solicitors Journal

Abortion may be legal in Argentina but women still face major obstacles – BBC

5 March 2023

Mara was 23 when she decided to have an abortion.

At the health centre where she had gone for treatment, she says she overheard one doctor saying to a colleague: "When will these girls learn to keep their legs closed?"

Mara lives in Salta, a religiously conservative province in north-west Argentina, where many healthcare workers are still against abortion.

She was eventually given a pill to end her pregnancy, but she says the nurses were reluctant to treat her and wanted to make her feel guilty: "After I expelled the pregnancy tissue, I could see the foetus."

"The nurses put it in a jar to make sure I saw it and they told me, 'This could have been your child.'"

Argentina relaxed its law on abortion in 2020, allowing a woman to choose to terminate her pregnancy in the first 14 weeks, Previously, it was only allowed in the case of rape or if the woman's life or health was at risk.

Abortion is a highly contentious issue in Argentina, where more than 60% of people are Catholic and 15% are evangelical Christians, with the leadership of both groups opposing the practice.

Maria says she was shown the foetus and told: "This could have been your child."

The new law allows health workers in Argentina to abstain from performing abortions.

"As soon as the law was passed, I declared myself a conscientious objector," says Dr Carlos Franco, a paediatrician from the same area as Mara, who estimates that 90% of health workers in the province's main public hospital have done the same.

He says his years studying embryology left him with the belief that life begins at fertilisation.

"My duty, as a doctor, is to take care and protect the human life from the embryonic stage," he adds.

This helps explain why women like Mara are having so much trouble accessing legal abortions.

Mara had initially spent two days at the health centre just waiting to be seen by a doctor.

Eventually, when none came, she turned to social media for help and found Mnica Rodriguez, a local activist, who helped her file a complaint at the hospital and secure an appointment.

Ms Rodriguez says she gets about 100 phone calls a month from women in Salta who are having similar difficulty getting access to safe abortions.

She tells the BBC her main job is simply to listen: "While I don't recommend abortion, I don't romanticise motherhood either."

The campaign to expand abortion rights in Argentina has taken decades, but Valeria Isla, director of sexual and reproductive health at the national health ministry, says that significant progress has been made.

She cites official figures showing that the number of mothers dying from abortions has dropped by 40% since the law was enacted in 2021.

The number of public health centres that provide abortions has gone up by more than a half over the same period, and the drug misoprostol, which chemically induces abortions, is now being manufactured in the country, making it more widely available.

Long waits for treatment and the social stigma surrounding abortions can make women vulnerable to corrupt practices.

There have been cases reported of women being forced to pay hundreds of dollars for treatment that should be free in public health facilities.

"There is a mafia," says Dr Mara Laura Lerma, a psychologist based in a remote mountain community in Jujuy in the country's north-west. "In many rural areas of Argentina, some doctors who work in the public hospital take patients to their private clinics."

The government has urged women to report allegations of corruption, but many women in rural areas are too scared to do so.

Anti-abortion activists are trying to block the law allowing the procedure

Doctors who do agree to perform abortions have been targeted with spurious legal complaints.

In September 2021, one doctor in Salta was briefly detained following an accusation by the aunt of a 21-year-old patient that she had performed an "illegal abortion".

The accusation was untrue, but it took a year for a court to dismiss the case.

"Anti-abortion organisations have historical connections with judges and people in power and they use them to generate fear and endanger the freedom of doctors who provide abortions," says Roco Garca Garro, a lawyer for pro-choice campaign group Catholics for the Right to Decide.

Anti-abortion campaigners are also using the courts to try and get the abortion law declared unconstitutional.

Cristina Fiore, a local parliament representative in Salta, is one of them.

"We believe human life starts at conception and we are against this throwaway culture," she says.

So far, all legal challenges have failed.

Mara is clear why she made the choice not to continue with her pregnancy: "I had never wanted to be a mum My parents abandoned me and that's a trauma which has taken me years to overcome."

She says she wants training to be improved for nurses and gynaecologists to prevent others suffering like her.

"There are many women, especially in the small rural towns, who are discriminated against like me and not all of them dare to speak."

*Names of some contributors have been changed to protect their privacy.

Continue reading here:
Abortion may be legal in Argentina but women still face major obstacles - BBC

Scientists urge pregnant women to avoid using plastic bottles – Daily Mail

By Xantha Leatham Deputy Science Editor For The Daily Mail 19:00 03 Mar 2023, updated 19:00 03 Mar 2023

Experts have recommended drinking out of glass or metal bottles due to growing fears that tiny plastic particles may wreak havoc on our health.

Dr Luisa Campagnolo, an expert in histology and embryology at the University of Rome Tor Vergata, warned there is mounting evidence that micro and nano-plastics are ending up in human tissue.

Previous studies have shown microscopic particles a byproduct of the degradation of plastic can end up in the human bloodstream and even the placenta.

But a new study in rats, presented at the American Association for the Advancement of Science's annual conference, shows ingested plastics can end up in the organs of the foetus itself.

'There are indications that most likely the foetus is a target for plastic particles, because the placenta is,' Dr Campagnolo, who was not involved in the study, said.

'I would avoid stuffing the placenta with plastic particles, in order not to have the foetus affected.'

Previous research has suggested plastic particles that penetrate human tissue can impact the production of certain hormones and may therefore impair biological processes.

And while research into the effect of plastic particles on human health is in its infancy, and it is important not to jump to conclusions about the potential dangers, there are simple steps we can all take to protect our health, Dr Campagnolo said.

Disposable plastic bottles can release debris, particularly when exposed to sunlight, which we then drink.

Dr Campagnolo said: 'It's probably less handy but we should not drink bottled water in plastic bottles.

'We don't have to freak out if we sit on a plastic chair, but I think we should avoid whatever is disposable, whatever is in contact with food, such as using plastic containers in the microwave oven. We should go back to glass.

'Disposable plastic took over probably 30 to 40 years ago but we can rethink this approach.'

Dr Philip Demokritou, an expert in nanoscience and environmental bioengineering at Rutgers University in New Jersey, said recent findings from animal studies were 'very alarming'.

His study in rodents, published last month in the journal Nanomaterials, is thought to show the first evidence that ingested plastics can be passed to a foetus.

He said: 'From the stomach of the pregnant animal, 24 hours later we found these micro- and nano-plastics in the placenta.

'More importantly, we found them in every organ of the foetus, which points to potential developmental effects.'

Dr Demokritou called for more investment in research to understand the implant of plastic particles on human health, and renewed efforts to recycle materials or switch to more biodegradable alternatives.

He said: 'I don't want to scare people but this is an emerging contaminant and we have a lot of unknowns in terms of the risks.

'Every person consumes roughly 5g of micro- and nano-plastics per week. That's the equivalent of a credit card going into your stomach on a weekly basis.

'We cannot go back to the Stone Age, but as a society we need to become smarter, embrace sustainable concepts, to avoid crises like this.

'All of us, scientists, the public, society at large, regulators, we need to rethink how we produce and use materials and chemicals in general.'

Urban flooding is causing microplastics to be flushed into our oceans even faster than thought, according to scientists looking at pollution in rivers.

Waterways in Greater Manchester are now so heavily contaminated by microplastics that particles are found in every sample - including even the smallest streams.

This pollution is a major contributor to contamination in the oceans, researchers found as part of the first detailed catchment-wide study anywhere in the world.

This debris - including microbeads and microfibres - are toxic to ecosystems.

Scientists tested 40 sites around Manchester and found every waterway contained these small toxic particles.

Microplastics are very small pieces of plastic debris including microbeads, microfibres and plastic fragments.

It has long been known they enter river systems from multiple sources including industrial effluent, storm water drains and domestic wastewater.

However, although around 90 per cent of microplastic contamination in the oceans is thought to originate from land, not much is known about their movements.

Most rivers examined had around 517,000 plastic particles per square metre, according to researchers from the University of Manchester who carried out the detailed study.

Following a period of major flooding, the researchers re-sampled at all of the sites.

They found levels of contamination had fallen at the majority of them, and the flooding had removed about 70 per cent of the microplastics stored on the river beds.

This demonstrates that flood events can transfer large quantities of microplastics from urban river to the oceans.

See original here:
Scientists urge pregnant women to avoid using plastic bottles - Daily Mail

Precongress courses at ESHRE23 characterised by practicality and … – ESHRE

Nineteen PCCs have been scheduled for this years annual meeting, 13 organised by ESHREs Special Interest Groups covering a wide range of themes and presenting speakers of international renown. A record number of abstracts have been received for the main scientific programme.

As ever, this years PCCs are characterised by a strong thread of practicality and topicality, with presentations from experts of international acclaim. Two of the courses, from the SIG Embryology and SIG Implantation & Early Pregnancy, will complement publication of two imminent ESHRE guidelines, on add-ons in ART and on recurrent implantation failure. Both guidelines have completed their stakeholder review and will be featured specifically in the courses. Add-ons, of course, have been a hot topic for ESHRE for several years, giving rise to a far wider general discussion of how to introduce new developments into everyday practice. The latter is the theme of a dedicated course from the SIG Global & Socio-cultural Aspects of Infertility, which is likely to be provocative at least, with presentations from among others Sebastiaan Mastenbroek, Simon Fishel, Jack Wilkinson and Ben Mol. Wilkinsons presentation has a strong practical theme on a subject which seems more usually beset by opinion - on how to introduce new technologies responsibly. Claims and counter-claims present a minefield for patients (help, hype and hope), which Manuela Perrotta hopes to unravel in her presentation on informed consent.

The SIG Implantation & Early Pregnancy describes recurrent implantation failure as a unique riddle, subject to different perspectives and putative solutions. These different perspectives are largely represented in a wide-ranging course which covers male, female and embryonic factors in a condition which affects 10% of the IVF population. Susan Golombok, from the Centre for Family Research in Cambridge, whose work has done so much to underline the acceptability of the new family dynamics which ART has made possible, will consider alternative approaches to parenthood. The daily routine of managing RIF patients will be reviewed by Bettina Toth.

Time-lapse systems are now ubiquitous in the IVF lab, especially in Europe, and they too feature prominently in this years PCCs, either in the practicality of new introductions or as a routine luxury or necessity. The latter features in a programme of debates organised by the SIG Reproductive Endocrinology, which also includes the hot topics of freeze-all, cycle programming ahead of FET, PGT-A for embryo selection, duo-stim and managing the luteal phase.

Two courses of great topical interest feature the introduction and application of artificial intelligence in reproductive medicine. Presentations will start with the basics and further consider how AI might help in embryo selection for transfer and endometrial receptivity. Even more topical, with the imminent revision of the EUs tissue and cell directives into a single directive, is a course organised by the SIGs Ethics & Law and Psychology & Counselling on the varying regulations in Europe on third-party gamete donation. Enhanced protection of donors is likely to be a major component of the new directive, and this PCC will consider how regulation has an impact on the practice of third-party donation.

Despite the vein of practicality running through many of these courses (indeed, the session on AI is sub-headed a practical course for IVF practitioners), basic science also figures prominently in sessions organised by the SIGs Andrology, Reproductive Genetics and Stem Cells. The theme for the course devised by the SIG Stem Cells concentrates on gametogenesis and attempts to model specific steps. Some of the technologies featured (such as IVM and the use of microfluidics) are already being applied clinically, while others are just emerging as potentially important.

Meanwhile, with the PCC schedule promising a feast of learning and attraction, news from the main programme is that a record number of abstracts had been received at ESHREs central office by submission deadline at end January. The total - of 2109 abstracts submitted - represents a new record and the first over 2000. The previous best was in Barcelona in the pre-covid days of 2018, when 1898 abstracts were received. After scoring and organisation into the selected oral communication sessions, the presentations will be made on the three days of the main programme, from Monday 26 June to Wednesday 28 June. The precongress courses will be held on Sunday 25 June, starting at 09.00

View original post here:
Precongress courses at ESHRE23 characterised by practicality and ... - ESHRE

Couple’s Child Has Deadly Cancer Gene Thanks to IVF Clinic’s … – The Daily Beast

Jason and Melissa Diaz thought they were giving their future child a shot at a healthy life when they opted for in vitro fertilization over natural conception. But according to a new lawsuit, what they got was nothing short of a disaster.

The California couple both carry genetic mutations: Melissa for BRCA-1, which predisposes carriers to breast cancer, and Jason for CDH1, which carries an elevated risk of stomach cancer.

Jason found out about his mutation in the summer of 2018, when he developed diffuse gastric cancer and was forced to undergo a gastrectomya full stomach removalwhen chemotherapy did not work. The life-altering procedure prevents patients from digesting food normally and causes chronic gastrointestinal pain, among other debilitating side effects.

When the Diazes decided to have children, they elected to go with IVF, so they could test the embryos for the genetic mutations before implanting them. According to the lawsuit, they wanted to achieve their dreams of parenthood without subjecting their children to the stomach cancer Jason and his family members had endured.

The fertility clinic they chose, HRC Fertility, advertises itself as having state-of-the-art embryology labs and remarkable lab personnel of highly trained and dedicated embryologists, according to the suit. It allegedly advertised their doctor, Bradford Kolb, as being known for helping to develop and implementing cutting edge technologies in the genetic screening of embryos.

From the beginning, they expressly advised HRC Fertility, its employees, and Dr. Kolb that they sought IVF with preimplantation genetic testing to avoid having a child with Jasons CDH1 mutation for hereditary diffuse gastric cancer, the suit states.

Jason and Melissa ultimately created five embryos with the clinic, only one of which did not carry either mutation, according to the suit. They transferred that embryo in August 2020, but Melissa ultimately miscarried.

Devastated but eager to try again, the suit claims, the Diazes asked their IVF coordinator to arrange for the implantation of a male embryo that the coordinator said carried the breast cancer mutation but not the stomach cancer mutation. (The couple considered this a safe choice because men are significantly less likely to develop breast cancer than women.)

Dr. Kolb transferred the embryo on Jan. 8, 2021, and Melissa gave birth to a boy in September. Jasons family threw a party for the couple to celebrate eliminating the CDH1 mutation from the Diaz family line, believing they had broken the curse that had doomed other family members to cancer and early death, the lawsuit states.

But the family was wrong. According to the suit, Dr. Kolb did not transfer a male embryo without the stomach cancer gene, because no such embryo existed. The IVF coordinator misrepresented the testing results and arranged for the transfer of a male embryo with the CDH1 mutation. The baby boy now has a more than 80 percent chance of developing stomach cancer, according to the suit.

We went through the difficult and expensive process of IVF so we could spare our children what Jason has had to endure, Melissa said at a press conference. We still cannot believe that after all we did ... our baby has the same genetic mutation we thought we escaped.

She added: Hes just such a happy baby, and to know the hurt in front of himthat he has to face for something we tried to preventit crushes me.

A spokesperson for HRC said in a statement that the Diazes had sought genetic testing and counseling outside of its facility, with a third party.

They wished to have a male embryo transferred, which we carried out according to the familys explicit wishes and in accordance with the highest level of care, the spokesperson said, adding that the company stand[s] by the professionalism and expertise of our medical staff and pride ourselves on adhering to the highest standards for patient care, patient records, results, and testing at all our locations.

According to the suit, the couples child will inevitably need to undergo a gastrectomy to prevent him from developing stomach cancer. They hope to delay the surgery until after he is finished developing, since removing the stomach before then could result in lifelong physical and cognitive impairments.

Jason, who saw two aunts die as a result of the cancer, called the results his greatest fear.

I wouldnt want anyone on earth to experience this type of pain, and now I will be forced to watch my own sonmy own flesh and bloodgo through this, he said. Every day my heart is hurting for my baby boy knowing the pain and challenges he has ahead of him.

Even if the child is able to delay the surgery until adulthood, he will still suffer from the pain, discomfort, and possible chronic diarrhea that afflicts many gastrectomy patients. The side effects may be so severe they will prevent him from taking certain jobs, according to the suit.

But the couple is not suing over the alleged wrongful implantation. Instead, they are alleging a coverup on the part of the fertility clinic, which they claim misled them even after the birth of their child.

According to the suit, the couple lived happily from September 2021 until July 2022, when they decided to try for another child. As part of this preparation, Melissa asked their new IVF coordinator to send over the report on the embryos they had created with HRC, so they could decide whichif anyof them they wanted to transfer.

What she saw on the report terrified her.

The embryo report, a copy of which is included in the complaint, contained handwritten notes that noted that the embryo transferred in January 2020the couples baby boywas positive for the stomach cancer mutation.

Melissa wrote back immediately, asking the coordinator to clarify whether the embryo theyd transferred carried the CDH1 gene. The coordinator did not respond. A week later, Melissa wrote again, saying the couple had been so stressed thinking of what our son will go through because of this genetic mutation.

Can you please double check that this is the correct report for our embryos? she wrote. Is there any way this could be a mistake? Again, the coordinator did not respond.

Eventually, the Diazes received a call from someone at HRC Fertility who admitted there had been a mistake, according to the suit, and called the couple in for a sit-down. When Melissa asked for a copy of her medical record, the clinic sent over a copy of the embryo report without the handwritten notes, the suit says, effectively removing the evidence of which embryo had been transferred.

HRC Fertility is one of the largest fertility clinics in the world, according to the suit, with nine offices across Southern California. The Pasadena office that the Diazes visited is a sprawling, 26,000-square-foot compound complete with luxurious VIP rooms, according to its website. According to the suit, the company is owned by Jinxin Fertility, one of the largest fertility companies in China.

Jinxin Fertility did not immediately respond to a request for comment.

HRC was also sued last summer by a same-sex couple who alleged that the center transferred a female embryo into their surrogate when they had explicitly requested a male. That suit, which also names Dr. Kolb as a defendant, is still pending in Los Angeles Superior Court.

A spokesperson for the company said last year that every child has value and limitless potential regardless of gender,'' and that they hoped the couple found love and value in their healthy child while so many across the country are struggling with reproductive issues.''

The Diazes have retained the services of Adam Wolf, an attorney known for his handling of IVF cases. Wolfs firm obtained a full copy of their medical record, handwritten notes included. They have initiated arbitration proceedings against HRC Fertility for the alleged wrongful transfer and are suing in California Superior Court for the alleged cover up.

The couple is requesting damages for their unimaginable mental anguish and for future lost wages and medical bills.

Tragically, this is yet another disaster in HRCs history of misusing patients genetic material and committing other grave fertility misconduct, Wolf said in a statement. In light of this history, I worry it will not be the last.

Excerpt from:
Couple's Child Has Deadly Cancer Gene Thanks to IVF Clinic's ... - The Daily Beast

Three-parent baby technique could create babies at risk of severe disease – MIT Technology Review

Fortunately, both babies were born to parents without genes for mitochondrial disease; they were using the technique to treat infertility. But the scientists behind the work believe that around one in five babies born using the three-parent technique could eventually inherit high levels of their mothers mitochondrial genes. For babies born to people with disease-causing mutations, this could spell disasterleaving them with devastating and potentially fatal illness.

The findings are making some clinics reconsider the use of the technology for mitochondrial diseases, at least until they understand why reversion is happening. These mitochondrial diseases have devastating consequences, says Bjrn Heindryckx at Ghent University in Belgium, who has been exploring the treatment for years. We should not continue with this.

Its dangerous to offer this procedure [for mitochondrial diseases], says Pavlo Mazur, an embryologist based in Kyiv, Ukraine, who has seen one of these cases firsthand.

Mitochondria are little energy factories that float around in the cytoplasm of our cells. While most of our DNA is housed in the nucleus of a cell, a tiny fraction resides in mitochondria. This mitochondrial DNA, or mtDNA, is only passed down from mothers to their children.

This becomes a problem when the mtDNA carries a disease-causing mutation. Mitochondrial diseases are rare, affecting around 1 in 4,300 people in the US. And researchers are still working out how many of these cases are caused by mutations in mtDNA, as opposed to other genetic changes. But they can have serious effects, including blindness, anemia, heart problems, and deafness. Some are fatal.

To avoid this, scientists have developed techniques that allow them to use mtDNA from a donor, along with DNA from a mother and father. These are generally called mitochondrial replacement therapies, or MRT.

There are a few different ways of doing this, but most teams use one of two approaches. Some scoop out the nuclei of two eggs, one from a prospective parent and one from a donor. Then they put the would-be parents nucleus into the egg of the donor, which still contains the cytoplasm, the fluid outside the nucleus that holds the mitochondria. The resulting egg can then be fertilized with sperm, creating an embryo that technically has three genetic parents.

Others first create a fertilized egg, called a zygote. Then they collect the DNA-containing nucleus of this zygote, which can be transferred to another fertilized egg that has had its own nucleus removed. The resulting zygote also has three genetic parents.

No one knows exactly how many babies have been born through MRT. Several clinics have described a handful of cases, mainly at conferences. An official trial at Newcastle Fertility Centre, in the UK, was launched in 2017.

Since then, the Newcastle clinic has received regulatory approval to perform MRT for 30 couples with a risk of passing a mitochondrial disease to their children, according to published minutes of the statutory approvals committee of the UKs regulatory body, the Human Fertilisation & Embryology Authority (HFEA). But the team has been extremely tight-lipped about the study and has avoided sharing any results with other researchers in the field.

A few other teams have been trying to learn whether the treatment works for infertility. Many couples struggle with unexplained infertility, and it is thought that the mix of proteins in the cytoplasm of an egg might somehow contribute to their inability to conceive. Because MRT essentially involves swapping the cytoplasm of one egg with that of another, some believe it might help treat some of these cases, and boost the success rates of IVF.

Dagan Wells, a reproductive biologist at the University of Oxford, is a member of one such team. Wells and his colleagues have also been trying to work out how safe the procedure is. Research in cells in a dish and in monkeys suggests there is a chance that MRT might not always prevent mitochondrial diseases. If this happens in people, it could have serious consequences.

When you scoop out nuclear DNA, it is difficult to completely avoid taking some of the cytoplasmincluding mtDNAalong with it. Embryologists have managed to limit the resulting so-called carryover to less than 1% of the embryos total mtDNA. Usually that 1% shouldnt be a concern, because the other 99% is healthy, says Shoukhrat Mitalipov, an embryo biologist at Oregon Health & Science University, who is collaborating with Wells.

But research by Mitalipov and others has shown that this figure can increase over time. Scientists call the phenomenon reversion. This reversion could be a problem in couples where the mother carries a mitochondrial disease. If the percentage of bad mtDNA gets too high, it could cause disease in the child.

To find out if this could occur in people, Wells, Mitalipov and their colleagues used MRT in 25 cisgender heterosexual couples, each of which had been through between three and 11 failed cycles of IVF. All of the women had been diagnosed with some form of infertility, and none had ever managed to become pregnant.

MRT is banned in the US, and the Newcastle clinic is the only one with approval to perform MRT in the UK, so the treatments were done at a clinic in Greece.

In each case, a woman with infertility first underwent standard IVF procedures that allowed doctors to collect a glut of her eggs. The spindles of these eggs, which contain the nuclear DNA, were then removed and put into eggs from a fertile donor that had already had their own nuclei removed. The resulting eggs were then fertilized with the male partners sperm to create embryos.

Once the embryos had started to develop, scientists took a couple of cells from them to look at their mitochondrial DNA. In all of the embryos, the vast majority of mtDNA came from the donor, with less than 1% from the infertile woman.

The team used a total of 122 maternal eggs and 122 donor eggs to generate 85 with donor mtDNA that were successfully fertilized with sperm. Twenty-four of these developed into healthy-looking embryos, and 19 of them were transferred to a womans uterus, resulting in seven pregnancies. One woman miscarried at nine weeks, but the other six pregnancies resulted in healthy babies, all of whom were born between the end of 2019 and 2020.

The team has also been checking the levels of mitochondrial DNA in the babies since they were born. The scientists have looked at DNA samples taken from swabs of the babies cheeks, as well as their urine, cord blood, and other blood samples. For five of the babies, the levels of their mothers mtDNA has remained low, at less than 1%. But something strange has happened in one of the children.

At the embryo stage, less than 1% of this childs mtDNA came from the woman with bad mtDNA, while over 99% came from the donor. But by the time the baby was born, the balance had shiftedwith between 30% and 60% of the mtDNA coming from the mother. Its almost 50:50, says Wells. Thats a huge swing. The results were published in the journal Fertility and Sterility in February.

We were hoping we wouldnt see [reversion] in babies, says Mitalipov. Now we have data to show that this is realnot just in monkeys but in humans.

Its the first time weve seen it in a person, says Matthew Prior, the head of department at the Newcastle fertility center. He said his team has not seen reversion in any babies born following MRTbut he also wont confirm if any MRT babies have been born there.

But while this is the first published report, a second case has been reported by doctors who performed the procedure at the Nadiya clinic in Kyiv, Ukraine. At an online meeting in 2020, Pavlo Mazur, then an embryologist at the clinic, told his colleagues about a baby boy who had also shown reversion.

The baby was one of 10 born in a pilot trial of MRT for infertility, says Mazur. He and his colleagues used a slightly different techniquethe one that involves first creating an embryo and then removing its nucleus. This is also the approach used by the Newcastle team in the UK.

The baby, born in 2019, was the second child of a woman who had undergone MRT twice. Her first baby, a girl born in 2017, didnt show any reversion, says Mazurher levels of mtDNA from her mother remained below 1%. But despite the fact that the same team used eggs from the same woman, and performed the same procedure at the same clinic, her baby brother was born with around 72% of his mtDNA coming from his mother.

We found it earlier [than Wells and his colleagues], says Mazur. We just never published it.

Because the parents didnt carry disease-causing genes in their mitochondria, these babies should be fine, says Wells. But, he says, if this family were [carrying mtDNA mutations], this would be a big concern60% is high, and it may cause disease.

Wells thinks it is difficult to predict how many babies might be affected by reversion. If his team did another 100 rounds of MRT, they might not see another case. Or they could see 90, he says: The sample size is really too small to say anything about the frequency of this.

But Mitalipov is more confident. On the basis of the current study and his previous work in cells and monkeys, he believes there is around a 20% risk of reversion following MRT. In other words, if MRT is used to avoid passing on disease-causing mtDNA, theres a one in five chance the baby will inherit potentially dangerous levels of that mtDNA anyway. Its not very rare, he says.

The question is whether these odds are acceptable. For infertile couples without a history of mitochondrial diseases, the risks of using the technique appear to be low. But scientists using MRT in an effort to prevent mitochondrial diseases may be creating babies who could become severely unwell.

A 20% risk might be acceptable for some couples, says Prior. He says the results dont change anything for the trial at Newcastle, which will continue as planned. Obviously we will follow these results, and in due course well publish our own results, he says.

Heidi Mertes, a medical ethicist at Ghent University, says that it is important to think about what would-be parents would do if the technology were not available. If they would try for a baby regardless, then perhaps an 80% reduction in the risk of passing on disease-causing mtDNA is acceptable. But if they might otherwise consider using a donor egg, or adopting a child instead, then those are better alternatives, she says.

For Joanna Poulton, a mitochondrial geneticist at the University of Oxford, the 20% risk of reversion is very concerning. Whats more, the risk could end up being much greater than that. There are mutations where quite low levels can cause problems, she says. For some diseases, the level can be as low as 15%, she says.

And this is all complicated by the fact that mtDNA is messy. We can find different levels of mutations in different organs of a single person, and people with a mix of mtDNA can pass down either disease-causing or healthy genes in their eggs. A baby with low levels of bad mtDNA in the blood could still have high levels in the brain or muscles. This was also seen in the monkeys born using MRT, says Mitalipov. In a single animal, he says, the level of bad mtDNA could be 90% in the liver, and maybe 0% in the blood.

To complicate things even further, these levels can change over time. A lot of these mutations progressively increase in life so symptoms will happen much later, says Heindryckx. Some mitochondrial diseases dont make themselves apparent until people reach adolescence, for example. This all makes it very difficult to predict how many babies might be at risk of developing serious disease.

The finding also has implications for another, more established method of preventing mitochondrial diseases in babies.

Before MRT was developed, some clinics used a technique called preimplantation genetic testing (PGT) to screen embryos for disease. It is possible to pinch a couple of cells from an embryo created using IVF and check for disease-causing mutations. Prospective parents have the opportunity to avoid implanting any embryos that have high levels of bad mtDNA.

But the current findings suggest that PGT might not always work. If the levels of mtDNA can change as an embryo or fetus develops, theres still a chance that the baby could be born with a disease. This might happen if disease-causing mtDNA replicates better than the healthy mtDNA. The balance between levels of good and bad mtDNA can change for the worse.

We dont know, says Heindryckx. His is one of many centers that have performed PGT for couples with mitochondrial disease but didnt follow up on the resulting children, he says. Its a wake-up call for us to do it more.

We do know of one case in which it does not seem to have worked. A baby was born from an embryo that PGT revealed to have around 12% of the mothers bad mtDNA. But by the time the baby was born, the proportion had shot up to around 50%. This baby had a plethora of symptoms, including atypical brain development, behavioral problems, and signs that he had experienced a brain hemorrhage.

Only a small number of babies have been born after using PGT to screen for mitochondrial disease, so again, its difficult to draw conclusions. The French center that pioneered the treatment, and has been offering it since 2006, recently reported that it has only had 29 babies born this way, says Heindryckx. His own center has only used it for the births of four or five babies in the last 10 years. And, as with MRT reversion, theres a chance that babies who are disease free at birth might get sick as they get older.

Its alarming, says Heindryckx. We should also be following up the babies born after PGT, because it could be that this reversion is also happening there.

What does this mean for MRT in the meantime? While the Newcastle team plans to proceed with its trial, others caution that, for the time being at least, we should pause the use of MRT for mitochondrial disease, and instead study it in people who dont have these diseases, such as those with infertility.

Mazur himself refuses to use MRT for mitochondrial disease. And Heindryckx says the risk is too high for himwith a 20% risk of reversion, he says, there is no way the ethical committee at his institution would allow him to use MRT for mitochondrial disease.

Mertes says she has never been a fan of the MRT trials. Scientists knew beforehand that the trials were never going to be risk free, and that they involve a potential waste of perfectly good donor eggs and embryos. In the end, youre presenting an option to patients that is more dangerous than their alternative, she says.

Experimental treatments like MRT also help to reinforce the idea that its very important for parents to have a genetic connection to their children, says Mertes. Wouldnt it be wiser to question whether its so important to have that genetic connection if the price you have to pay is a health risk for your child? she asks. Parents can avoid all the risks that come with MRT by opting to use a donated egg in place of their own, or adopting a child, for example.

In the meantime, clinics that offer MRT need to update the information they provide so that people know that this is a very real risk that theyre taking, says Mertes. And both she and Prior think that the treatment should be restricted to those who need it or at least are adamant that they want a genetic link to their children.

Mitalipov is confident that scientists like himself will eventually come up with a solution to mitochondrial reversion. We just need to figure out why it happens, he says. So far, no clue but just give us time.

Follow this link:
Three-parent baby technique could create babies at risk of severe disease - MIT Technology Review

UK ministers urged to consider changing law to allow genome editing of human embryos: Report – WION

COMMERCIAL BREAK

SCROLL TO CONTINUE READING

A citizens' jury in the United Kingdom (UK) has urged ministers to consider changing the law to allow scientists to carry out genome editing of human embryos for serious genetic conditions. The jury is made up of individuals whose lives have been affected by the hereditary disease. The report, published in Wellcome Connecting Science, has made "15 recommendations centered around transparency, inclusivity and equal access to treatment that should be considered in deciding whether to legalise editing of human embryos to treat genetic diseases."

According to Cambridge University on Tuesday (February 28), over 2.4 million people in the UK are currently living with a genetic condition. This includes disorders, such as cystic fibrosis or sickle cell anaemia, which are caused by variations in a single gene and can be inherited in families.

It is illegal (in the UK) to perform genome editing on embryos that lead to pregnancy, the university said. "The NHS does offer a service to couples who carry a heritable genetic trait to screen IVF embryos, meaning only embryos without the inherited condition are implanted. However, this approach is not suitable for everyone," it added.

The views of the individuals most affected by genetic conditions are timely due to two reasons, the 3rd International Summit on Human Genome Editing starting on Monday (March 6) and UK legislation due to be debated in parliament later this year.

Professor Anna Middleton,the leader of the project from Wellcome Connecting Science and the University of Cambridge,said that though all jurors have personal experience of an inherited genetic condition, their views on the editing of human embryos were varied, nuanced and complex.

"Many of the discussions were emotional, and the responsibility felt by the jurors to represent wider society in their deliberations was clear," Middleton said.

She added that when the Human Fertilisation and Embryology Act is debated in Parliament and discussions emerge on the editing of human embryos, it is imperative that the voices of patients are heard as part of this.

Andrea-Reid Kelly, one of the jurors said that before the jury, she did not know much about editing of human embryos or have a strong opinion about it. "Im a bit of a fence-sitter by nature. But by the end of the jury, I went from a neutral opinion to being in favour of parliamentary debate about potentially changing the law to allow editing of human embryos to treat genetic conditions," Kelly said.

Kelly was born with a significant heart condition, which was later learnt to be caused by Noonan syndrome. She said this is a genetic condition that can cause heart problems, distinctive facial features, small stature and specific learning difficulties such as dyslexia. She had heart surgery when she was four years old and then again when she was 33.

"So far as we know, neither of our daughters has Noonan syndrome. Because the gene that causes my case is unknown, we cant test them to know for sure," she added. Kelly also said that she met another person with the syndrome some years ago, and could identify with their experience and bond over challenges.

Another juror,Brenda Poku, suffers from sickle cell disease and her brother also has the condition. Sickle cell disease is a genetic condition caused by a faulty gene that affects the shape of red blood cells. One of the most common symptoms is bouts of pain, which are very unpredictable in timing and severity, sometimes requiring strong painkillers like morphine or even hospitalisation.

This condition is particularly common in people with African or Caribbean ancestry. Poku is originally from Ghana and moved to the UK to study for her doctorate. "I was originally a nurse, but now I research sickle cell disease from the perspective of patient experience and service provision," she said.

"Being in healthcare, I had some knowledge of genome editing before I took part in the citizens jury. There are advanced genome editing trials for sickle cell disease, with some of the participants having been cured. Researchers are monitoring them to make sure there are no unintended long-term side effects, but its likely there will be a cure for sickle cell in my lifetime," Poku said.

"During the jury event, I gained a new appreciation of why some people may want to take advantage of human embryo editing and would say that swayed me towards thinking it needed to be considered," she added.

(With inputs from agencies)

WATCH WION LIVE HERE

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Originally posted here:
UK ministers urged to consider changing law to allow genome editing of human embryos: Report - WION